User:Mr. Ibrahem/Afatinib

Afatinib, sold under the brand name Gilotrif among others, is a medication used to treat non-small cell lung carcinoma (NSCLC). It is mainly used in advanced cases with a non-resistant epidermal growth factor receptor (EGFR) mutation. It is taken by mouth.

Common side effects include diarrhea, rash, mouth inflammation, dry skin, nausea, and itchiness. Other side effects may include interstitial lung disease, liver problems, gastrointestinal perforation, and corneal inflammation. Use in pregnancy may harm the baby. It is a tyrosine kinase inhibitor which blocks a family of proteins known as ErbB.

Afatinib was approved for medical use in the United States and Europe in 2013. It is on the World Health Organization's List of Essential Medicines as an alternative to erlotinib. In the United Kingdom 4 weeks costs the NHS about £2,000 as of 2021. This amount in the United States costs about 9,800 USD.